Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
3.020
-0.150 (-4.73%)
Apr 25, 2025, 11:53 AM EDT - Market open
Clene Revenue
In the year 2024, Clene had annual revenue of $342.00K, down -47.71%. Clene had revenue of $91.00K in the quarter ending December 31, 2024, a decrease of -46.47%.
Revenue (ttm)
$342.00K
Revenue Growth
-47.71%
P/S Ratio
64.46
Revenue / Employee
$4,500
Employees
76
Market Cap
26.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walmart | 680.99B |
Costco Wholesale | 264.09B |
PepsiCo | 91.85B |
The Procter & Gamble Company | 84.35B |
Unilever | 62.91B |
Anheuser-Busch InBev | 59.77B |
The Coca-Cola Company | 47.06B |
Philip Morris International | 37.88B |
CLNN News
- 11 days ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 24 days ago - Clene to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewsWire
- 4 weeks ago - Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 6 weeks ago - Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment - GlobeNewsWire
- 7 weeks ago - Clene to Present at the 37TH Annual Roth Conference - GlobeNewsWire
- 2 months ago - Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 - Accesswire
- 2 months ago - Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction - GlobeNewsWire
- 4 months ago - FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - GlobeNewsWire